



**To:** MaineCare Providers  
**From:** Jan Wright, Interim Director of  
Pharmacy  
**Date:** April 2, 2021  
**Re:** PDL Update for **04/02/2021**

**The following medication(s) have recently been added to the MaineCare PDL as preferred and with new PDL criteria:**

Orladeyo is for the treatment of patients  $\geq 12$  years of age and clinical PA is required to establish diagnosis and medical necessity.

Sofosbuvir/velpatasvir (authorized generic labeler Asegua) approvals will require clinical PA. Please see the Hepatitis PA form for criteria.

**The following medication(s) have been recently added/changed to the MaineCare PDL as non-preferred and will require prior authorization.**

Barhemsys	Fyavolv	Reditrex
Bentyl Syrp	Monjuvi	Sutab
Centrum Silver Tabs	Pennsaid	Twirla
Epclusa	Phexxi	Verquvo

**The following medication(s) have recently been added to the MaineCare PDL as non-preferred and with new PDL criteria:**

Eysuvis is for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

Impeklo is for the treatment of patients  $\geq 18$  years of age.

Oxlumo clinical PA is required to establish diagnosis and medical necessity.

Betimol Soln, Cortisporin Soln, Enuclene Soln, Foradil Aerolizer Caps, Thyroid Tabs and Thyrolar have been removed from the PDL.